TCM
DMIIU

Tuttle Capital Management’s Drugs Made In America Acquisition II Corp Unit DMIIU Stock Holding History

Tuttle Capital Management’s Portfolio DMIIU Stock Details DMIIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-25,000
Closed -$249K – 117
2025
Q3 		$249K Buy
+25,000
New +$249K 0.94% 45

Other funds holding DMIIU

MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
SCM
Steadfast Capital Management New York $3.26B AUM 36.54% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $3.04B AUM 26.78% 1-Year Est. Return

Tuttle Capital Management's DMIIU Position: Q4 2025 in Review

Tuttle Capital Management sold out of Drugs Made In America Acquisition II Corp Unit (DMIIU) in Q4 2025, closing a stake of 25,000 shares — an estimated $249K sold.

Tuttle Capital Management first reported a position in DMIIU in Q3 2025 and held it in 1 quarter. The position peaked at $249K in Q3 2025. 30 funds tracked by Wall St. Rank hold DMIIU as of Q4 2025.

  • Tuttle Capital Management reported no remaining Drugs Made In America Acquisition II Corp Unit position as of Q4 2025 after selling out during the quarter.
  • Tuttle Capital Management sold 25,000 Drugs Made In America Acquisition II Corp Unit shares in Q4 2025, an estimated $249K.
  • Tuttle Capital Management first reported a position in Drugs Made In America Acquisition II Corp Unit in Q3 2025 and held it in 1 quarter.
  • Tuttle Capital Management's Drugs Made In America Acquisition II Corp Unit position peaked at $249K in Q3 2025.
  • 30 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp Unit as of Q4 2025.

Based on Tuttle Capital Management's 13F filing for Q4 2025, filed 8 Jan 2026.